小教堂
发表于 2025-3-30 11:41:46
http://reply.papertrans.cn/19/1852/185123/185123_51.png
专心
发表于 2025-3-30 15:48:31
http://reply.papertrans.cn/19/1852/185123/185123_52.png
山间窄路
发表于 2025-3-30 20:13:41
https://doi.org/10.1007/978-94-009-0793-5poor prognosis with a median overall survival time of only 9–15 months. The infiltrating nature of the tumour cells, inter- and intra-tumoral molecular heterogeneity and the tumour’s propensity to hide behind the blood-brain barrier are the key causes of the insufficiency of the optimal available tr
悠然
发表于 2025-3-30 21:51:29
http://reply.papertrans.cn/19/1852/185123/185123_54.png
anaerobic
发表于 2025-3-31 01:35:06
International Corporate Brand Managementand survival. Targeted cancer therapeutics are amongst the major treatment options for cancer today. These treatments are more selective for cancer cells and improve the quality of life for cancer patients undergoing therapy. Nevertheless, cardiotoxicity is a frequent side effect in targeted therapi
最高峰
发表于 2025-3-31 05:36:43
http://reply.papertrans.cn/19/1852/185123/185123_56.png
未成熟
发表于 2025-3-31 09:41:23
https://doi.org/10.1007/978-3-658-00406-4heir scientific basis, further aspects are important for new medical procedures to be introduced into broad clinical care. In this matter, we in Germany have special experiences with PET which is still not fully recognized by statutory health insurances as the standard procedure of choice for many i
Obverse
发表于 2025-3-31 14:44:36
International Courts and Mass Atrocity(theranostics) of prostate cancer, particularly in the metastatic castrate-resistant state. Numerous investigations from around the world in both academic and pharma settings are focused on research and development of safe and effective PSMA-based theranostic agents. Encouraging results from retrosp
扔掉掐死你
发表于 2025-3-31 19:42:35
Understandings of Law in Croatia, 1980s and ended up with radiomolecular precision oncology in 2020s. The author also had own interests which Richard Baum did not touch. The author worked some time with oligonucleotide radionuclide therapy (radionanotargeting) in the 1990s learning that it will be impossible in clinical practice. O